Health Industry Heads Into Turbulent Waters Amid Financial and Regulatory Shifts

Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate health outlook declining, a proposed GST exemption in India, a US emergency authorization for animal drugs, Novo Nordisk's market challenges, and significant investments in healthcare technology by EliseAI.

In a significant setback for Viking Therapeutics, shares plummeted 41% after its weight-loss pill VK2735 failed to meet Wall Street's high-end expectations in a recent trial. The drug only facilitated a 12.2% weight loss in patients, below the anticipated 15% benchmark, stirring investor disappointment.

The European corporate health outlook sees a minor dip as earnings growth expectations adjusted to 4.6%, down from the projected 4.8%. This marks a reversal from the recent trend of improvement in corporate profits, indicating potential economic challenges.

Andreessen Horowitz spearheaded a massive $250 million funding round for EliseAI, doubling its valuation past $2.2 billion. The funding aims to bolster the company's presence in healthcare automation, indicating robust investor confidence in healthcare technology innovations.

(With inputs from agencies.)